ClinicalTrials.gg
Active, not recruitingNCT06681532Updated Jan 8, 2026

Bovine Pericardium Membrane Versus Native Collagen Membrane in Conjunction With Sticky Bone Graft in Treatment of Class II Furcation Defects in Lower Molars.

An interventional study of Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars and Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars in Furcation Defects, sponsored by Ibrahim Ahmed Zein Elabdin Ahmed. Active, not recruiting at 1 site in Egypt. Per ClinicalTrials.gov, last updated 2026-01-08.

Sponsored by Ibrahim Ahmed Zein Elabdin Ahmed · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as active, not recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Sex
All
01

Study summary

Materials and methods: Twenty five patients (n=25) were selected from the outpatient clinic of the department of oral medicine and periodontology at Mansoura university's faculty of dentistry, 5 patients (n=5) were excluded as they didn't meet the inclusion criteria or met one or more of the exclusion criteria.

The participants 20 patients exhibiting one buccal or lingual mandibular molar furcation defect were assigned into two treatment groups: group I (control group), group II (study group), 10 patients in each group.

Patients in group I will be treated with open flap debridement, native collagen membrane and bovine bone graft particles. Patients in group II will be treated with open flap debridement, bovine pericardium membrane and bovine bone graft particles.

Periodontal assessment (plaque index (PI), gingival index (GI), horizontal clinical attachment level (HCAL), vertical clinical attachment level (VCAL), gingival recession (REC) and probing depth (PD)) will be evaluated at baseline, 3 months and 6 months after periodontal treatment.

Radiographic assessment using CBCT (bone loss in the horizontal direction (BL-H), bone loss in vertical direction (BL-V), length of the root trunk (RT), width of furcation entrance (FW) will be evaluated at baseline and 6 months after periodontal treatment.

Read the detailed description

Study population:

The randomized controlled clinical trial includes 20 participants selected from the outpatient clinic of the department of oral medicine and periodontology at Mansoura university's faculty of dentistry from July 2024 to September 2024. All the patients exhibits one buccal or lingual mandibular molar furcation defect.

Study Design:

A double blinded, parallel group randomized controlled trial. The participants were randomly assigned using a computer random number generator program into two treatment groups:

  • Group 1: The control group, includes 10 patients with class II furcation defects in lower molars and will be treated with open flap debridement, native collagen membrane and bovine bone graft particles.
  • Group 2: The study group, includes 10 patients with class II furcation defects in lower molars and will be treated with open flap debridement, bovine pericardium membrane and bovine bone graft particles.

Surgical procedure:

Two weeks prior to surgery, using ultrasonic scaler tips and micro curettes, the remaining periodontal pocket will be treated. Only the exposed root surface and the first 3 mm of the root beneath the periodontal pocket will be instrumented. In order to guarantee proper manipulation, surgery won't start until the marginal tissue has a fibrous tone and there is little to no inflammation.

Following injection of local anesthetic (articaine/epinephrine 1:100,000), sulcular incisions will be made, a full thickness flap will be elevated at the furcation site, extending at least one tooth mesial and distal to the affected tooth, and extending beyond mucogingival junction for adequate accessibility. Furcation micro curettes and ultrasonic scalers will be used to fully debride and clean the furcation area, and then the area will be carefully irrigated with saline.

After this, In (Group 1\&2), the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the defect area will be condensed with the mixture and covered completely with native collagen membrane (group 1) or bovine pericardium membrane (group 2), both will be trimmed, adapted and placed so as to completely cover the grafted area and the adjacent 2-3 mm of bone tissue. Bioabsorbable ligatures will be used to secure the membrane to the soft tissues adjacent to the site of regeneration, preventing graft movement and membrane collapse. Afterwards, the flaps will be repositioned and securely sutured.

All patients will be prescribed amoxicillin 500 mg every 8 hours for duration of 5 days (azithromycin 500 mg once daily for 3 days for patients allergic to amoxicillin). Postoperative pain and inflammation will be managed with ibuprofen 600 mg (or acetaminophen 1g for patients allergic to ibuprofen). Patients will be instructed to rinse with 0.2% chlorhexidine twice daily for one week, without engaging in mechanical hygiene in the surgical area. Sutures will be removed after one week, and patients will be advised to perform mechanical cleaning of the area using a soft brush and apicocoronal brushing.

Follow-up visits will be scheduled at 1, 2, 3, and 4 weeks to assess patient-reported feedback, adherence to postoperative instructions and , clinical examination (Parameters such as bleeding, swelling, discomfort -eating and speech-, and pain are evaluated), as well as at 3 and 6 months, also incorporating supportive periodontal therapy and reinforcement of oral hygiene practices.

Periodontal assessment:

The clinical assessment will be performed at baseline, 3 months and 6 months after periodontal treatment.

  1. Probing depth (PD), measured from the free gingival margin to the bottom of the sulcus.
  2. Horizontal clinical attachment level (HCAL) is measured with Naber's probe measure the depth of FI.
  3. Vertical clinical attachment level (VCAL), measured using UNC-15 probe from cemento-enamel junction to the bottom of the sulcus.
  4. Gingival recession (REC), measured on the buccal aspect, at the level of the central axis of the tooth, from the CEJ to the gingival margin.
  5. Plaque index (PI), introduced by Silness and Loe in 1964.
  6. Gingival Index (GI), developed by Loe and Silness in 1963.

Radiographic assessment:

Radiographic interpretation of the furcation defect will be done using CBCT small field of view of the operated site taken for hard tissue assessment, at baseline and 6 months post-operatively.

The three axes (axial, sagittal, and coronal) of the CBCT images will be analyzed continuously. The linear measurements of the dimension of bone loss in the horizontal and vertical directions (BL-H, BL-V), root trunk (RT), and furcation width (FW) will be assessed.

  • Bone loss in the horizontal direction (BL-H): using the axial view to measure the distance between the outer root surface and the inter- radicular bone, measured to the nearest millimeter.
  • Vertical bone loss (BL-V): using the sagittal view to measure the distance from the furcation entrance (FE) to the base of the defect (BD) in the vertical direction.
  • Length of the root trunk (RT): using the sagittal view to measure the distance from the cementoenamel junction (CEJ) to the furcation entrance (FE).
  • Width of furcation entrance (FW): using the axial or sagittal view to measure the widest mesial-distal distance in the furcation.

This study is conducted following guidelines regulating research work on human subjects of the Faculty of Dentistry, Mansoura University, and the study protocol was reviewed and approved by the Research Ethics Committee of the Faculty of Dentistry, Mansoura University, Egypt. (Number: A05030240M)

Sample size calculation was based on efficacy of using a bovine pericardium membrane with a bovine bone graft versus a native collagen membrane with bovine bone graft for treatment of class II furcation defects, retrieved from previous research ( Serroni et al., 2022). Using G power program version 3.1.9.7 to calculate sample size based on effect size of 0.816 ,using 2-tailed test , α error =0.05 and power = 90.0% , the total calculated sample size will be 8 in each group at least .

Pretreatment period, Patients receive detailed information about their treatment, including potential effects, risks, and alternative options. The patients must have a broad understanding of this explanation and be legally competent to provide written consent before any necessary procedures.

Statistical Assessment:

Data will be analyzed using statistical package for social sciences (SPSS) version 22. Qualitative data will be presented as number and percent, Quantitative data will be tested for normality by Shapiro-Wilk test then described as mean and standard deviation for normally distributed data and median and range for non-normally distributed. The appropriate statistical test will be applied according to data type with the following suggested tests: Chi-Square for categorical variable, Spearman or Pearson correlation will be used to correlate continuous variables. : Kruskal Wallis test and One Way ANOVA test for non-normally and normally distributed data for more than 2 independent groups.

02

Conditions studied

  • Furcation Defects

Browse trials for

03

In context

Furcation Defects

42 studies on the registry are indexed under Furcation Defects; 13 are open to participants now.

This study's enrollment of 20 is below the median of 27 across 38 interventional studies indexed under Furcation Defects.

Browse Furcation Defects studies →

Lead sponsor

This is the only study on the registry with Ibrahim Ahmed Zein Elabdin Ahmed as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Display a buccal or lingual class II furcation defect (Hamp et al. classification) in their lower molars.
  • The tooth with a horizontal clinical attachment level (HCAL) greater than 3mm and a probing depth (PD) greater than or equal to 6mm in the mid-buccal or mid-lingual sites.
  • Have not undergone any periodontal treatment in the past 6 months.
  • A plaque index score (PI) below 1 at surgery, assessed using the Ramfjord teeth.

Exclusion criteria

Exclusion Criteria:

  • Patients with class I or class III furcation defects.
  • Systemic disease contraindicating periodontal surgery.
  • Taking any medication that may have an impact on their periodontal health within the last 6 months.
  • Smoking.
  • Being pregnant or lactating.
  • Teeth with periapical lesions and teeth with mobility.
  • Third molars or teeth with improper endodontic or restorative treatment.
  • Patients with furcation caries, metal crowns in the furcation area or amalgam fillings near the alveolar crest.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (actual)

Study arms

  • Active comparator
    Control group

    Are treated with open flap debridement, native collagen membrane and bovine bone graft particles.

    Procedure: Native collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars

  • Experimental
    Study group

    Are treated with open flap debridement, bovine pericardium membrane and bovine bone graft particles.

    Procedure: Bovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars

Interventions

  • ProcedureNative collagen membrane and bovine bone graft in treatment of class II furcation defects in lower molars

    The bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with native collagen membrane.

  • ProcedureBovine pericardium membrane and bovine bone graft in treatment of class II furcation defects in lower molars

    the bovine bone graft particles will be mixed with concentrated growth factor (CGF) to form sticky bone, the furcation defect area will be condensed with the mixture and covered completely with bovine pericardium membrane.

06

What researchers measure

Primary outcomes

  1. Clinical ( Horizontal clinical attachment level [HCAL] )

    Is measured with Naber's probe, measure the depth of Furcation.

    Time frame: 6 months

  2. Radiographic ( Bone loss in the horizontal direction [BL-H] )

    Using the CBCT axial view to measure the distance between the outer root surface and the inter-radicular bone.

    Time frame: 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06681532
Lead sponsor
Ibrahim Ahmed Zein Elabdin Ahmed
Responsible party
Ibrahim Ahmed Zein Elabdin Ahmed (BDS, Principal Investigator, Oral Medicine, and Periodontology Department., Mansoura University) — Sponsor-investigator
First posted
Nov 8, 2024
Start date
Sep 1, 2024
Primary completion
Feb 2026 (estimated)
Completion
Mar 2026 (estimated)
Last update
Jan 8, 2026

Study contacts

Ibrahim A Zein Elabdin
principal investigator · Mansoura university Faculty of dentistry

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion